Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Molecular Profile | ROS1 fusion ROS1 G2032R |
| Therapy | Zidesamtinib |
| Indication/Tumor Type | lung non-small cell carcinoma |
| Response Type | predicted - sensitive |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| ROS1 fusion ROS1 G2032R | lung non-small cell carcinoma | predicted - sensitive | Zidesamtinib | Phase I | Actionable | In a Phase I trial (ARROS-1), Zidesamtinib (NUV-520) treatment demonstrated safety and activity in patients with non-small cell lung cancer harboring a ROS1 fusion, including a response rate of 65% (11/17) with a median duration of response of 15.8 months in repotrectinib-naive patients and a response rate of 38% (3/8) in repotrectinib-pretreated patients harboring a ROS1 fusion and ROS1 G2032R (Ann Oncol (2024) 35 (Suppl_2): S804-S805; NCT05118789). | detail... |
| PubMed Id | Reference Title | Details |
|---|---|---|
| Safety and preliminary clinical activity of NVL-520, a highly selective ROS1 inhibitor, in patients with advanced ROS1 fusion-positive solid tumors | Full reference... |